| Product Code: ETC13408421 | Publication Date: Apr 2025 | Updated Date: Sep 2026 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 190 | No. of Figures: 80 | No. of Tables: 40 |
| Market Size (2025) | USD 12.8 Billion |
| Forecast Size (2032) | USD 20.3 Billion |
| CAGR | 6.80% |
| Base Year | 2025 |
| Forecast Period | 2026-2032 |
| Largest Region | North America |
| Fastest Growing Region | Asia |
| Largest Segment | Respiratory Disease |
| Fastest Growing Segment | Tropical Disease |
| Leading Companies | Abbott Laboratories, Thermo Fisher Scientific, Roche, Cepheid, BD |

The Global Infectious Disease Pointofcare Testing Market was estimated at USD 12.8 Billion in 2025 and is projected to reach USD 20.3 Billion by 2032, growing at a CAGR of 6.80% from 2026 to 2032.
The landscape of the Global Infectious Disease Pointofcare Testing Market is evolving rapidly, influenced by the urgency for swift diagnostics amid the resurgence of infectious diseases. The shift toward decentralized testing directly addresses the needs of healthcare systems facing mounting pressures to deliver immediate results. Moreover, the integration of user-friendly technologies enhances testing accuracy and accessibility.
Key segments within this market are adapting to heightened healthcare demands. In particular, respiratory and tropical diseases are at the forefront, driving investments in innovative diagnostic measures. The market's distinct nature stems from its focus on immediate, localized testing, setting it apart from traditional laboratory diagnostics which follow a longer processing timeline.
This graph illustrates the annual growth rates of the Global Infectious Disease Pointofcare Testing Market from 2022 to 2032, highlighting a steady upward trajectory and projected expansion over the forecast period.

The table below presents the year‑wise growth rates along with the key drivers influencing the market
| Year | Growth Rate (%) | Major Drivers |
| 2022 | 4.51 | Implementing sustainable practices in point-of-care testing enhances clinical trial pipelines and environmental responsibility. |
| 2023 | 7.18 | In North America, workforce advancements in point-of-care testing improve patient outcomes data collection. |
| 2024 | 7.78 | As global supply chain dynamics stabilize, point-of-care testing distribution becomes more efficient and reliable. |
| 2025 | 6.37 | Expanding telehealth platforms enables consumers to access infectious disease point-of-care testing remotely. |
| 2026 | 6.29 | A shift toward reducing input costs in biosensor technology enhances affordability in point-of-care testing. |
| 2027 | 9.01 | Hospitals expanding their infrastructure establish greater access to infectious disease point-of-care testing devices. |
| 2028 | 6.06 | Healthcare providers adopting digital therapeutics are increasingly favoring innovative point-of-care testing solutions. |
| 2029 | 5.32 | Consumer preference for rapid test results signals a significant evolution in infectious disease point-of-care testing. |
| 2030 | 6.78 | FDA approvals for novel point-of-care diagnostic tools are transforming the regulatory backdrop for testing. |
| 2031 | 6.69 | Increased investment in biosensor technology stimulates advancements in infectious disease point-of-care testing capabilities. |
| 2032 | 7.56 | Manufacturers innovating in portable testing devices cater to rising needs in infectious disease diagnostics. |
Note - Market size estimations and growth projections presented in this report are based on 6Wresearch's proprietary research methodology, combining internal industry data, secondary research, and primary validation, updated periodically to reflect current market conditions. As markets evolve rapidly, figures for certain industries may vary slightly and are intended as informed estimates rather than absolute figures. For the most current market sizing, we recommend validating figures with a 6Wresearch analyst.
Below are some of the specific key takeaways from the market, including:
Despite the promising outlook, the Global Infectious Disease Pointofcare Testing Market encounters notable challenges. High implementation costs are a primary restraint, with estimates suggesting an average expenditure of USD 25,000 per installation of point-of-care testing devices in healthcare facilities. Regulatory hurdles can delay product approval, adding an additional layer of complication; for instance, the FDA's 510(k) process outlines stringent requirements that must be met for device clearance. For example, many manufacturers face significant financial burdens without guaranteed market access, leading to hesitance in investment decisions.
Several critical trends are actively shaping the Global Infectious Disease Pointofcare Testing Market. First, there is a noticeable shift toward integrated diagnostics, where companies integrate digital health technologies with testing. Abbott, for example, introduced the ID NOW platform, which not only provides results in minutes but also connects to mobile applications to help track patient outcomes. Furthermore, multi-pathogen testing is gaining traction, allowing for the detection of several diseases simultaneously; market players such as Cepheid are investing heavily in these capabilities, underscoring a changing operational paradigm. Another emerging trend is AI integration, where firms utilize algorithms to enhance testing accuracy and streamline workflows in clinical settings, markedly affecting how diagnostics are approached.
The market is ripe with opportunities for future revenue growth. One significant area is the expansion of point-of-care testing in emerging regions, where limited access to laboratories hampers timely diagnosis. Companies like Thermo Fisher are actively pursuing initiatives aimed at launching affordable testing solutions tailored to these markets. Another key area involves the increased focus on early disease detection; projects funded by governmental bodies are emphasizing the importance of swift identification and treatment of infectious diseases. For instance, by 2025, initiatives could allocate upwards of USD 10 million toward enhancing diagnostic infrastructure in rural territories. This trend signals an opening for partnerships and new market entrants committed to addressing diagnostic gaps.
Among the segments of the Global Infectious Disease Pointofcare Testing Market, Respiratory Disease leads with an estimated market share of ~50% in 2025. This prominent share can be attributed to the high prevalence of respiratory infections globally and the urgent need for rapid testing solutions, especially in the context of pandemics. Conversely, Tropical Disease is the fastest-growing segment, expected to achieve a CAGR of 9.2% from 2026 to 2032. This accelerated growth arises from rising investments in vector control and disease prevention initiatives, particularly in resource-limited settings where emerging infectious diseases present significant challenges.
In the technological landscape of the Global Infectious Disease Pointofcare Testing Market, Lateral Flow Testing is the leading method, capturing an approximately ~55% share as of 2025. This dominant position results from the technology's simplicity and ease of use, enabling quick results even in resource-limited environments. Meanwhile, Agglutination Assays are the fastest-growing technology, projected to achieve a CAGR of 8.9% from 2026 to 2032. This increase is fueled by their enhanced accuracy and lower cost, which make them attractive for high-throughput settings.
Among end-users, Hospitals hold the largest share of the Global Infectious Disease Pointofcare Testing Market, commanding approximately ~60% share in 2025. Their preference for advanced diagnostic capabilities and immediate results explains this dominance. In contrast, Home-care Settings are the fastest-growing segment, anticipated to experience a CAGR of 8.0% from 2026 to 2032. The growing trend towards patient-centered care significantly contributes to this expansion, with an increasing number of companies offering user-friendly POC testing devices catering to at-home users.
North America stands as the largest region in the Global Infectious Disease Pointofcare Testing Market, with an approximate market share of ~45% in 2025. The region’s advanced healthcare infrastructure and robust investment in diagnostic technologies contribute to its leadership. On the other hand, Asia emerges as the fastest-growing region, expected to witness a CAGR of 8.5% from 2026 to 2032. This growth is attributable to increasing healthcare expenditures and a rising focus on improving access to medical diagnostics in underserved areas, fostering a healthy ecosystem for POC testing developments.
The regulatory landscape surrounding the Global Infectious Disease Pointofcare Testing Market is characterized by a commitment from various governments to enhance healthcare accessibility and improve diagnostic capabilities. Initiatives aim to stimulate innovation while ensuring the safety and effectiveness of point-of-care products, shaping the market environment effectively.
The trajectory of the Global Infectious Disease Pointofcare Testing Market is likely to shift toward advanced technologies and integrated solutions. For instance, as seen with Abbott's ID NOW platform, the integration of digital tools will enhance real-time health data management, allowing providers to adapt swiftly to emerging health threats. The expansion of telehealth services will also foster an environment where POC testing becomes increasingly essential, amplifying the focus on early disease detection initiatives driven by global health organizations.
Several recent developments underscore the dynamic changes within the Global Infectious Disease Pointofcare Testing Market. Each initiative reflects a strategic move to enhance testing capabilities, broaden market reach, and address specific healthcare challenges.
The competitive landscape of the Global Infectious Disease Pointofcare Testing Market is moderately consolidated, with a few key players leading in technology and market share. These companies are strategically positioned to leverage their expertise in diagnostics, which enhances their ability to respond to emerging infectious threats effectively.
| Leading Company | Core Strength | Strategic Focus |
|---|---|---|
| Abbott Laboratories | Market leader in rapid diagnostics solutions | Expanding POC testing across respiratory infections |
| Thermo Fisher Scientific | Strong R&D capabilities and product innovation | Focused on affordable testing solutions for emerging markets |
| Roche | Pioneering diagnostics technology and data integration | Enhancing rapid testing platforms for infectious diseases |
| Cepheid | Expertise in molecular diagnostics for complex infections | Targeting tropical diseases and underdiagnosed conditions |
| BD | Robust manufacturing and distribution network | Acquiring technologies to enhance testing efficiency |
As the market evolves, these key players are expected to maintain their competitive advantages through innovation and strategic collaborations, significantly influencing future market dynamics.
Markets Covered
The Global Infectious Disease Point-of-care Testing Market report provides a detailed analysis of the following market segments:
By Regions and Countries:
By Applications:
By Technologies:
By End-users:
The Global Infectious Disease Point-of-care Testing Market report provides a detailed analysis of the following market segments:
Global Infectious Disease Point-of-care Testing Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Global Infectious Disease Point-of-care Testing Market Overview |
3.1 Global Regional Macro Economic Indicators |
3.2 Global Infectious Disease Point-of-care Testing Market Revenues & Volume, 2022 & 2032F |
3.3 Global Infectious Disease Point-of-care Testing Market - Industry Life Cycle |
3.4 Global Infectious Disease Point-of-care Testing Market - Porter's Five Forces |
3.5 Global Infectious Disease Point-of-care Testing Market Revenues & Volume Share, By Regions, 2022 & 2032F |
3.6 Global Infectious Disease Point-of-care Testing Market Revenues & Volume Share, By Applications, 2022 & 2032F |
3.7 Global Infectious Disease Point-of-care Testing Market Revenues & Volume Share, By Technologies, 2022 & 2032F |
3.8 Global Infectious Disease Point-of-care Testing Market Revenues & Volume Share, By End-users, 2022 & 2032F |
4 Global Infectious Disease Point-of-care Testing Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Global Infectious Disease Point-of-care Testing Market Trends |
6 Global Infectious Disease Point-of-care Testing Market, 2022-2032 |
6.1 Global Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Applications, 2022-2032 |
6.1.1 Overview & Analysis |
6.1.2 Global Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Tropical Disease, 2022-2032 |
6.1.3 Global Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Liver Disease, 2022-2032 |
6.1.4 Global Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Respiratory Disease, 2022-2032 |
6.1.5 Global Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Sexual Disorders, 2022-2032 |
6.1.6 Global Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Others, 2022-2032 |
6.2 Global Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Technologies, 2022-2032 |
6.2.1 Overview & Analysis |
6.2.2 Global Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Lateral Flow, 2022-2032 |
6.2.3 Global Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Flow-through, 2022-2032 |
6.2.4 Global Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Agglutination Assays, 2022-2032 |
6.2.5 Global Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Solid Phase, 2022-2032 |
6.3 Global Infectious Disease Point-of-care Testing Market, Revenues & Volume, By End-users, 2022-2032 |
6.3.1 Overview & Analysis |
6.3.2 Global Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Diagnostic Laboratories, 2022-2032 |
6.3.3 Global Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Hospitals, 2022-2032 |
6.3.4 Global Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Home-care Settings, 2022-2032 |
6.3.5 Global Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Others, 2022-2032 |
7 North America Infectious Disease Point-of-care Testing Market, Overview & Analysis |
7.1 North America Infectious Disease Point-of-care Testing Market Revenues & Volume, 2022-2032 |
7.2 North America Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Countries, 2022-2032 |
7.2.1 United States (US) Infectious Disease Point-of-care Testing Market, Revenues & Volume, 2022-2032 |
7.2.2 Canada Infectious Disease Point-of-care Testing Market, Revenues & Volume, 2022-2032 |
7.2.3 Rest of North America Infectious Disease Point-of-care Testing Market, Revenues & Volume, 2022-2032 |
7.3 North America Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Applications, 2022-2032 |
7.4 North America Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Technologies, 2022-2032 |
7.5 North America Infectious Disease Point-of-care Testing Market, Revenues & Volume, By End-users, 2022-2032 |
8 Latin America (LATAM) Infectious Disease Point-of-care Testing Market, Overview & Analysis |
8.1 Latin America (LATAM) Infectious Disease Point-of-care Testing Market Revenues & Volume, 2022-2032 |
8.2 Latin America (LATAM) Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Countries, 2022-2032 |
8.2.1 Brazil Infectious Disease Point-of-care Testing Market, Revenues & Volume, 2022-2032 |
8.2.2 Mexico Infectious Disease Point-of-care Testing Market, Revenues & Volume, 2022-2032 |
8.2.3 Argentina Infectious Disease Point-of-care Testing Market, Revenues & Volume, 2022-2032 |
8.2.4 Rest of LATAM Infectious Disease Point-of-care Testing Market, Revenues & Volume, 2022-2032 |
8.3 Latin America (LATAM) Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Applications, 2022-2032 |
8.4 Latin America (LATAM) Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Technologies, 2022-2032 |
8.5 Latin America (LATAM) Infectious Disease Point-of-care Testing Market, Revenues & Volume, By End-users, 2022-2032 |
9 Asia Infectious Disease Point-of-care Testing Market, Overview & Analysis |
9.1 Asia Infectious Disease Point-of-care Testing Market Revenues & Volume, 2022-2032 |
9.2 Asia Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Countries, 2022-2032 |
9.2.1 India Infectious Disease Point-of-care Testing Market, Revenues & Volume, 2022-2032 |
9.2.2 China Infectious Disease Point-of-care Testing Market, Revenues & Volume, 2022-2032 |
9.2.3 Japan Infectious Disease Point-of-care Testing Market, Revenues & Volume, 2022-2032 |
9.2.4 Rest of Asia Infectious Disease Point-of-care Testing Market, Revenues & Volume, 2022-2032 |
9.3 Asia Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Applications, 2022-2032 |
9.4 Asia Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Technologies, 2022-2032 |
9.5 Asia Infectious Disease Point-of-care Testing Market, Revenues & Volume, By End-users, 2022-2032 |
10 Africa Infectious Disease Point-of-care Testing Market, Overview & Analysis |
10.1 Africa Infectious Disease Point-of-care Testing Market Revenues & Volume, 2022-2032 |
10.2 Africa Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Countries, 2022-2032 |
10.2.1 South Africa Infectious Disease Point-of-care Testing Market, Revenues & Volume, 2022-2032 |
10.2.2 Egypt Infectious Disease Point-of-care Testing Market, Revenues & Volume, 2022-2032 |
10.2.3 Nigeria Infectious Disease Point-of-care Testing Market, Revenues & Volume, 2022-2032 |
10.2.4 Rest of Africa Infectious Disease Point-of-care Testing Market, Revenues & Volume, 2022-2032 |
10.3 Africa Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Applications, 2022-2032 |
10.4 Africa Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Technologies, 2022-2032 |
10.5 Africa Infectious Disease Point-of-care Testing Market, Revenues & Volume, By End-users, 2022-2032 |
11 Europe Infectious Disease Point-of-care Testing Market, Overview & Analysis |
11.1 Europe Infectious Disease Point-of-care Testing Market Revenues & Volume, 2022-2032 |
11.2 Europe Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Countries, 2022-2032 |
11.2.1 United Kingdom Infectious Disease Point-of-care Testing Market, Revenues & Volume, 2022-2032 |
11.2.2 Germany Infectious Disease Point-of-care Testing Market, Revenues & Volume, 2022-2032 |
11.2.3 France Infectious Disease Point-of-care Testing Market, Revenues & Volume, 2022-2032 |
11.2.4 Rest of Europe Infectious Disease Point-of-care Testing Market, Revenues & Volume, 2022-2032 |
11.3 Europe Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Applications, 2022-2032 |
11.4 Europe Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Technologies, 2022-2032 |
11.5 Europe Infectious Disease Point-of-care Testing Market, Revenues & Volume, By End-users, 2022-2032 |
12 Middle East Infectious Disease Point-of-care Testing Market, Overview & Analysis |
12.1 Middle East Infectious Disease Point-of-care Testing Market Revenues & Volume, 2022-2032 |
12.2 Middle East Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Countries, 2022-2032 |
12.2.1 Saudi Arabia Infectious Disease Point-of-care Testing Market, Revenues & Volume, 2022-2032 |
12.2.2 UAE Infectious Disease Point-of-care Testing Market, Revenues & Volume, 2022-2032 |
12.2.3 Turkey Infectious Disease Point-of-care Testing Market, Revenues & Volume, 2022-2032 |
12.3 Middle East Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Applications, 2022-2032 |
12.4 Middle East Infectious Disease Point-of-care Testing Market, Revenues & Volume, By Technologies, 2022-2032 |
12.5 Middle East Infectious Disease Point-of-care Testing Market, Revenues & Volume, By End-users, 2022-2032 |
13 Global Infectious Disease Point-of-care Testing Market Key Performance Indicators |
14 Global Infectious Disease Point-of-care Testing Market - Export/Import By Countries Assessment |
15 Global Infectious Disease Point-of-care Testing Market - Opportunity Assessment |
15.1 Global Infectious Disease Point-of-care Testing Market Opportunity Assessment, By Countries, 2022 & 2032F |
15.2 Global Infectious Disease Point-of-care Testing Market Opportunity Assessment, By Applications, 2022 & 2032F |
15.3 Global Infectious Disease Point-of-care Testing Market Opportunity Assessment, By Technologies, 2022 & 2032F |
15.4 Global Infectious Disease Point-of-care Testing Market Opportunity Assessment, By End-users, 2022 & 2032F |
16 Global Infectious Disease Point-of-care Testing Market - Competitive Landscape |
16.1 Global Infectious Disease Point-of-care Testing Market Revenue Share, By Companies, 2025 |
16.2 Global Infectious Disease Point-of-care Testing Market Competitive Benchmarking, By Operating and Technical Parameters |
17 Top 10 Company Profiles |
18 Recommendations |
19 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here